Breaking Research News from sources other than Breastcancer.org

Options
1…94959799100…104

Comments

  • GoKale4320
    GoKale4320 Member Posts: 599
    edited November 2021

    MoCoGram - here is the email address for Dr. Germino

    joseph_f.germino@bayer.com



    · Share on FacebookShare on Twitter
  • Lumpie
    Lumpie Member Posts: 1,650
    edited November 2021

    Someone asked about METAvivor funding for research. METAvivor has a research funding application process. It takes place once or twice a year. Petitioners must complete a grant application. This is typical in the grant application/research "space." Applicants are scored and ranked by a scientific team and by patient advocates team. Scoring relates to chance of success and potential impact. A board makes final decisions about awards. Those interested in applying can find more info on the METAvivor website.

    · Share on FacebookShare on Twitter
  • Lumpie
    Lumpie Member Posts: 1,650
    edited November 2021

    Sharing this update from the American Cancer Society's Cancer Action Network:

    Exciting news! We have recently released some initial findings of our last Survivor Views survey, which focuses on patient experiences with telehealth and issues around clinical trial participation. As noted by ACS CAN president Lisa Lacasse in today's press release, "These data suggest we have a real opportunity to make clinical trial participation easier for all patients by removing barriers to participation, including through the use of telehealth technologies and reducing out-of-pocket costs."

    To all those who responded to our Summer 2021 survey, THANK YOU! You've contributed your voice to our mission of improving the lives of cancer patients and survivors. With the Survivor Views project, we do this by making sure you are heard by the decision makers shaping health policy.

    If you haven't yet responded to our current survey, which covers topics like paid medical leave for patients and caregivers, please click the following link to respond by November 15th:

    https://survey.us.confirmit.com/wix/p925353504545.aspx

    {If you are interested in signing up for the ACS Cancer Action Network, you can do so here:

    https://www.fightcancer.org/

    The group does both advocacy and fundraising. You can pick and choose your level of participation.}

    · Share on FacebookShare on Twitter
  • BSandra
    BSandra Member Posts: 836
    edited November 2021

    A very interesting episode (there are more - please check): https://www.ourmbclife.org/episodes/rtac-lin-parso...

    Also lot's of useful information and articles.

    Saulius

    · Share on FacebookShare on Twitter
  • Anonymous
    Anonymous Member Posts: 1,376
    edited November 2021

    Thanks for that link Saulius! Great conversation.

    · Share on FacebookShare on Twitter
  • jennyjo20
    jennyjo20 Member Posts: 41
    edited November 2021

    https://investor.lilly.com/news-releases/news-rele...


    FDA has approved Verzenio for HR+ HER2 -, node positive high-risk early breast cancer

    "This subgroup analysis (N=2,003) included patients with ≥4 positive axillary lymph nodes (ALN), or 1-3 positive ALN with either Grade 3 disease and/or tumor size ≥5 cm, and whose tumors had a Ki-67 score of ≥20%. There was also a statistically significant improvement in IDFS for this pre-specified subgroup of patients receiving Verzenio plus ET compared to those who received ET alone."

    "The number of IDFS events at the time of this analysis was 104 with Verzenio plus ET compared to 158 with ET alone."

    · Share on FacebookShare on Twitter
  • HomeMom
    HomeMom Member Posts: 1,198
    edited November 2021

    Jenny - man that stuff has some bad side affects.

    · Share on FacebookShare on Twitter
  • jennyjo20
    jennyjo20 Member Posts: 41
    edited November 2021

    HomeMom,

    Thankfully, I don't meet their definition of "high-risk", so I won't be adding this to my treatment regimen. But if I did, I would be happy to know that this was an additional option to help prevent metastatic recurrence.

    · Share on FacebookShare on Twitter
  • Lumpie
    Lumpie Member Posts: 1,650
    edited November 2021

    FDA is Moving Away from the Maximum Tolerated Dose!

    The decades-long paradigm of leveraging the highest and most toxic dose of a cancer drug, called the Maximum Tolerated Dose (MTD), will be coming to an end.

    Shortly after the PCDI's presentation about MBC patients' treatment-related side effects at ASCO's 2021 worldwide conference, Richard Pazdur, Director of the FDA's Oncology Center of Excellence, stated that the FDA will start requiring drug companies to test the efficacy of multiple drug doses during clinical trials instead of identifying and moving forward with the MTD.

    This is a game-changer because the MTD, which is identified in Phase 1 clinical trials that focus solely on toxicity, is the dose that generally causes the most severe side effects. In today's world, whenever patients with MBC begin a new treatment, they are generally prescribed the MTD unless there's a medical contraindication. But in tomorrow's world, at least two doses will be identified in Phase 1 clinical trials for further study so that ultimately the optimal dose - based upon a balance of efficacy and toxicity - will be given to patients.

    If this subject interests you, please consider joining a webinar hosted by Friends of Cancer Research on Wednesday, Nov. 10th at 12PM ET. Panelists including the FDA, pharmaceutical companies, Friends of Cancer Research, and the PCDI, will be discussing the transformation of MTD-based oncology studies.

    You may register here for the free conference!

    Thank you,

    Anne Loeser, Author,Founder PCDI

    {The above is from an email dated 11/6/2021 from Anne Loesser. Some of you may have received it. This is great news IMO. Less toxicity while maintaining efficacy is what we all want. I believe that the Friends of Cancer Research session on Patient Centered Dosing is only one hour long.}

    · Share on FacebookShare on Twitter
  • Karenfizedbo15
    Karenfizedbo15 Member Posts: 717
    edited November 2021

    Hi Lumpie, re MTD can I just jump in and say that I have NEVER tolerated the Max Dose of pretty much any cancer drug. I’ve had a few now and they have always required reductions because the side effects are just awful. So far we’ve managed to get to a reasonable level albeit with plenty of side effects. I agree that we should not be accepting the max dose just because that’s where the clinical trials are pitched. Much more research required!

    · Share on FacebookShare on Twitter
  • leftfootforward
    leftfootforward Member Posts: 1,726
    edited November 2021

    the discussion about max dose jogged a memory. I was told that it is known that a lot of people won’t be able to tolerate the max dose and it is expected that there will be dose reductions. I can’t remember the exact reason, but studies are done at max dose because it’s easier to dose reduce than to get approval for a dose increase. Meaning, you can always prescribe it for a lower dose than it’s approved for use for, but you can’t prescribe it at a dose it wasn’t tested and approved for ( higher). Therefore the starting dose is often higher than what some people can tolerate.

    This is from my memory of when I was on Xeloda and had to do a dose reduction and from discussions I had. When I was in a clinical trial.

    · Share on FacebookShare on Twitter
  • Lumpie
    Lumpie Member Posts: 1,650
    edited November 2021

    I saw a very interesting presentation on the steps in a clinical trial and exactly how they determine the maximum tolerated dose and it had discussion about determinations around what dose reductions are "officially" permitted. It was a really good presentation. If I can find a link, I will post it, but ... I don't know... it's been a while....

    · Share on FacebookShare on Twitter
  • Lumpie
    Lumpie Member Posts: 1,650
    edited November 2021

    If you missed the Friends of Cancer Research presentation on....

    Maximizing Benefit and Improving Tolerability for Patients Through Dose Optimization

    Here are the links:

    Click HERE to Watch
    Click HERE to access the Pre-Conference White Paper.

    It is about 1 hour long.

    · Share on FacebookShare on Twitter
  • moth
    moth Member Posts: 4,800
    edited November 2021

    Treatment landscape of triple-negative breast cancer — expanded options, evolving needs

    Nature Reviews: Clinical Oncology Nov 2021

    https://t.co/pxmnyjVNvj?amp=1

    covers early stage as well as metastatic setting. Link is publishers complimentary access - might expire at some point. main link: https://www.nature.com/articles/s41571-021-00565-2 & doi https://doi.org/10.1038/s41571-021-00565-2

    · Share on FacebookShare on Twitter
  • LillyIsHere
    LillyIsHere Member Posts: 830
    edited November 2021

    Atlas of Lobular Breast Cancer Models: Challenges and Strategic Direction
    https://www.mdpi.com/2072-6694/13/21/5396/htm

    · Share on FacebookShare on Twitter
  • BSandra
    BSandra Member Posts: 836
    edited November 2021

    Dear All, a very interesting summary on ongoing/future research in ADCs with tables of main clinical trials: https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21705#caac21705-bib-0119

    · Share on FacebookShare on Twitter
  • Tinkerbell107
    Tinkerbell107 Member Posts: 281
    edited November 2021

    News > Medscape Medical News > Conference News

    Survival Doubled in 2 Types of Met Breast Cancer, Says Expert:


    Unfortunately I can't seem to send a link. However you can join medscape for free to read the article. Recent update on survival trends.

    · Share on FacebookShare on Twitter
  • moth
    moth Member Posts: 4,800
    edited November 2021

    Tinkerbell, thanks for posting that.

    https://www.medscape.com/viewarticle/962953#vp_1

    For those who can't access it, the positive trends are ER+ and HER2+ - not a real surprise is it?

    "Patients with two of the three major types of advanced breast cancer now have a median overall survival of at least 5 years, which is roughly a doubling of survival time over the past decade, says an expert."

    The only positive thing said about TNBC was that trodelvy improved our survival by 5 months. Not much of yippeee for mTNBC :( Honestly, I feel like throwing up - I'm so tired of triple neg. I'm so tired to of mbc support groups being dominated by people with more favourable diagnosis. If I hear thriver one more time I'm going to scream. Oh dear, maybe this should be in the steam room....

    But yay, I'm glad for the ER+ and HER2+ peeps!

    · Share on FacebookShare on Twitter
  • LillyIsHere
    LillyIsHere Member Posts: 830
    edited November 2021

    Moth, aren't you ER+ now? I am sorry if I am mistaken but from your signature, it seems that you moved to ER+, and hopefully, letrozole will keep it under control for a very, very long time.

    · Share on FacebookShare on Twitter
  • moth
    moth Member Posts: 4,800
    edited November 2021

    Lilly, no, I have one met which tested faintly er+ but so faint that they consider me triple neg still. We added the letrozole just in case but honestly nobody thinks it's doing anything and it was debatable whether I should have started it.

    My original biopsy also had a very faint trace of er+ which they struggled to categorize. Oncotype has me as triple neg and we've been treating as triple neg.

    · Share on FacebookShare on Twitter
  • Tinkerbell107
    Tinkerbell107 Member Posts: 281
    edited November 2021

    Moth: Thanks for adding to my failed attempt with sending a link. I attended a virtual conference on Sunday for MBC. There was positive chatter for mTNBC, especially w PARPi and Pik3 mutation (utilizing PIqray if + positive for the mutation.) besides or in combo with immunotherapy.

    · Share on FacebookShare on Twitter
  • LillyIsHere
    LillyIsHere Member Posts: 830
    edited November 2021

    I'm sorry Moth. I had this hope of having ER+ in order for letrozole to work. Hugs.

    · Share on FacebookShare on Twitter
  • moth
    moth Member Posts: 4,800
    edited November 2021

    alas,I've been tested & have no somatic or germline brca or pik3ca mutations. I have had a good run on immunotherapy + chemo. By mTNBC standards I've done well so I shouldn't complain but you know how it is...5 years is the stuff dreams are made of for me.

    · Share on FacebookShare on Twitter
  • LaughingGull
    LaughingGull Member Posts: 560
    edited November 2021

    I am sorry, moth. The article about the doubling of the survival time arrived to my Inbox a couple of days ago, and my first thought was of compassion towards every patient out there reading this who has triple negative mbc. I specifically thought of you, because although I don't know you, I always read your insightful advice and comments in this forum. I send you a big, big hug, sister. You are not alone. Very very sorry. You had such bad luck. Here is for your dream becoming true, for you making it to the five years, and then for some breakthrough drug that tames that cancer freaking beast that we hate so much. And yes, you absolutely can complain.

    · Share on FacebookShare on Twitter
  • Tess111
    Tess111 Member Posts: 58
    edited November 2021

    Moth, LaughingGull said everything I wanted to say (except SO much better than I could have written.) I always read your posts because they are so insightful and filled with useful information. You make a difference - probably to a lot more people than you can imagine. Thank you for that. Sending you a virtual hug, to be used any time you need it and for as many times as you need it.

    · Share on FacebookShare on Twitter
  • BSandra
    BSandra Member Posts: 836
    edited November 2021

    Dear All, ESMO Immuno-oncology has amazing seminars on 08-11/12/2021. I find day 2 (9th) very intriguing, especially TIL, TCR, CAR-T, and multi-specific engagers in solid tumors. Please, whoever has time, follow: https://cslide.ctimeetingtech.com/immuno2021v/attendee/confcal/session/calendar/2021-12-09

    Cell therapies and bispecific agents in the pipeline

    Date: Thu, 09.12.2021, Time: 14:30 - 16:00 Room Room A, Chairs: Marco Donia (Herlev, Denmark)
    · Share on FacebookShare on Twitter
  • BevJen
    BevJen Member Posts: 2,523
    edited November 2021

    Saulius,

    Thanks for posting. Odd that ESMO overlaps with SABCS? I thought they generally ran at different times.

    · Share on FacebookShare on Twitter
  • moth
    moth Member Posts: 4,800
    edited November 2021

    awww, LaughingGull & Tess, thank you so much. You made me cry - but in a good way, kwim...

    BevJen, I did a double take at that too because I was sure I'd followed some ESMO sessions this year...then I thought maybe that was last year & I'm really out of it? But no, main ESMO is over already. They have an immunology mini congress. I'm signed up for SABCS so not sure how I'll organize my time. (and fit in all my hallmark xmas movies!!! priorities!... lol)

    · Share on FacebookShare on Twitter
  • moth
    moth Member Posts: 4,800
    edited November 2021

    regarding the Bayer ErSO, just saw a screenshot of someone else's correspondence & it's bad news - they're NOT proceeding to Phase 1 trials at this time https://twitter.com/LibbyMbc/status/14606547735022...


    · Share on FacebookShare on Twitter
  • GoKale4320
    GoKale4320 Member Posts: 599
    edited November 2021

    Thanks, Moth, for passing on this information about ErSO. What a lucky turn of events. Looks like only mice have a cure.

    I have an appointment at Dana Farber to see what further treatment I should pursue and to see if I might qualify for the ErSO clinical trial. I probably should cancel it since I can now clearly see the path of maybe 3 different CDK4/6 inhibitors and then nothing.




    · Share on FacebookShare on Twitter

Categories